GSA Capital Partners’s Forte Biosciences FBRX Stock Holding History

GSA Capital Partners’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,060	Closed	-$75K	–	1513
2022 Q1	$75K	Buy	+2,060	New	+$77.9K	0.01%	1321
2021 Q4	–	Sell	-2,051	Closed	-$152K	–	1517
2021 Q3	$152K	Buy	+2,051	New	+$1.14M	0.02%	1281
2020 Q1	–	Sell	-729	Closed	-$146K	–	1209
2019 Q4	$146K	Buy	729 +662	+988%	+$150K	0.02%	1306
2019 Q3	$17K	Sell	67 -153	-70%	-$232K	﹤0.01%	1344
2019 Q2	$551K	Buy	+220	New	+$652K	0.06%	607

Other funds holding FBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GSA Capital Partners's FBRX Position: Q2 2022 in Review

GSA Capital Partners sold out of Forte Biosciences (FBRX) in Q2 2022, closing a stake of 2,060 shares — an estimated $75K sold.

GSA Capital Partners first reported a position in FBRX in Q2 2019 and held it in 5 quarters. The position peaked at $551K in Q2 2019. 39 funds tracked by Wall St. Rank hold FBRX as of Q2 2022.

GSA Capital Partners reported no remaining Forte Biosciences position as of Q2 2022 after selling out during the quarter.
GSA Capital Partners sold 2,060 Forte Biosciences shares in Q2 2022, an estimated $75K.
GSA Capital Partners first reported a position in Forte Biosciences in Q2 2019 and held it in 5 quarters.
GSA Capital Partners's Forte Biosciences position peaked at $551K in Q2 2019.
39 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2022.

Based on GSA Capital Partners's 13F filing for Q2 2022, filed 9 Aug 2022.